MedPath

the effect of tofacitinib on bone mineral density in patients with rheumatoid arthritis

Phase 4
Conditions
to determine the effect of tofacitinib on bone
Registration Number
JPRN-UMIN000027242
Lead Sponsor
Division of rheumatology, hiroshima clinic
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up continuing
Sex
All
Target Recruitment
50
Inclusion Criteria

Not provided

Exclusion Criteria

patients had received steroids, bisphosphonates, or parathyroid hormone.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
the comparison of the BMD of the lumbar spine and femoral neck at baseline and 52 weeks after tofacitinib treatment.
Secondary Outcome Measures
NameTimeMethod
the comparison of the bone marker at baseline and 52 weeks after tofacitinib treatment
© Copyright 2025. All Rights Reserved by MedPath